Federal Circuit disqualifies Katten
from Mylan appeals
The US Court of Appeals for the Federal Circuit yesterday disqualified
law firm Katten Muchin Rosenman from representing Mylan in three appeals before
the court. In a precedential decision handed down on February 20, the Federal
Circuit ruled that Katten’s representation of subsidiaries of Canadian pharma
company Valeant Pharmaceuticals International presented a conflict of interest…..
Accord vs. NPS; District Court of The
Hague 6 February 2019 [Cinacalcet]
Shire-NPS Pharmaceuticals Inc. (“NPS”) was the patentee of
EP 1 203 761 B1 (“EP 761”) titled “Calcium receptor-active compounds” that was
granted on 19 January 2005. The subject matter of EP 761 is, inter alia, the
pharmaceutical compound cinacalcet, which is used for the treatment of
hypercalcemia and related diseases (in essence, cinacalcet, helps the body
maintaining normal calcium levels). On the basis of EP 761, a supplementary
protection certificate was granted by the Dutch Patent Office to Amgen for the
product Mimpara (the “SPC”) which SPC expires on 25 April 2020…..
Judge Stark on Privilege for Patent
Agents [KYPROLIS® (carfilzomib)]
In a Memorandum Order unsealed on February 19, Chief Judge
Stark addressed disputes over Plaintiff Onyx’s privilege log. Before making
rulings on specific documents reviewed in camera, Judge Stark ruled generally
as to the extent of the applicable privilege. Judge Stark first recognized that
the Federal Circuit has recognized a privilege between non-attorney patent
agents and their clients, but that such a privilege is narrow. Onyx
Therapeutics, Inc. v. Cipla Limited, C.A. No. 16-988-LPS….
Amgen Asks Fed. Circ. To Uphold $70M
Hospira IP Verdict [EPOGEN® (Epoetin alfa)]
Law360 (February 21, 2019, 4:52 PM EST) -- Amgen Inc. has
asked the Federal Circuit to preserve a $70 million jury verdict finding that
Hospira’s biosimilar version of the blockbuster anemia treatment Epogen
infringed an Amgen patent, saying Hospira...
Indian
court says Sinopharm Weiqida’s amoxicillin trihydrate product infringes
Centrient patent
Netherlands-based Centrient Pharmaceuticals, a manufacturer
of beta-lactam antibiotics, and a provider of next generation statins and
anti-fungals, announced that the Delhi High Court in India has granted an
injunction against Sinopharm Weiqida Pharmaceuticals and Sinopharm India,
restricting the export and/or import into India of its active pharmaceutical
ingredient (API) amoxicillin trihydrate……
No comments:
Post a Comment